Research Activities

Page 1 of 1

Below are the research projects that Endeavour is currently pursuing.

Verifying the validity of urinary kryptopyrrole testing

Project Lead Investigator: Dr Amie Steel

Urinary kryptopyrrole testing has been used since the 1960s to assist in the diagnosis and management of mental health disorders. Despite this long history of use, there has been minimal formal study into the validity of the testing. The Office of Research, in collaboration with SAFE Analytical Laboratories Pty Ltd (SAFE Labs), is undertaking research using SAFE Labs' urinary kryptopyrrole test in both a healthy adult population, and an adult population with diagnosed anxiety. It is hoped that a clear reference interval for urinary kryptopyrroles can be established in both of these population, enabling better patient management, and providing suitable data for registration of the test in Australia.

Phase I Trial Assessing the Safety of Carb Starver. (SOCS)

Project Lead Investigator: Dr Janet Schloss

Ketogenic diets are typically high in fat and low in carbohydrates and are often adopted for a strategy to lose weight. Inducing a state of ketosis is normally achieved by dietary modification and is generally a slow process that requires the body go through a set of stages before entering ketosis. Typically, it takes at least three days of following a ketogenic diet for a subject to enter a state of ketosis. The difficulty with strict dietary models is that they are difficult to manage, maintain and control.

This is a safety trial to assess any changes in blood glucose, ketone levels, liver and kidney function from consuming this product which gives you a form of ketones. It is a one day trial for healthy individuals aged 18-75 years of age. During the one day trial participants will be monitored after two doses and reassessed two days later.

A Phase 2 Randomised, Double Blind Clinical Trial Assessing the Tolerability of two Different Rations of Medicinal Cannabis in Patients with Glioblastoma Multiforme (GMB)

Project Lead Investigator: Dr Janet Schloss

This world first clinical trial investigating whether medicinal cannabis can benefit patients with malignant brain tumours is being led by Clinical Trials Manager Dr Janet Schloss from the Office of Research and supported by internationally renowned neurosurgeon Professor Charlie Teo. Based on recent studies, medicinal cannabis may slow the growth of tumours particularly aggressive gliomas, as such it is essential to conduct further clinical research in this area. Investigating the appropriate dosage guidelines and understanding whether medicinal cannabis has a role to play in reducing tumour size and the development of new glioma tumours for patients is imperative. Assessing this area could be life changing for individuals living with the disease and their families. This phase 2 clinical trial will examine whether high THC medicinal cannabis can be tolerated by people with glioma (a type of brain tumour) and if it can affect tumour growth when administered with standard medical treatment. This trial is funded by BioCeuticals, Australia's leading provider of nutritional and therapeutic supplements, who have invested $500,000 as part of their commitment to provide practitioners with evidence-based solutions for health conditions.

Nocturnal Enuresis Randomised Controlled Clinical Trial

Project Lead Investigator: Dr Janet Schloss

Bed wetting, or the medical term 'nocturnal enuresis', is a form of night time urinary incontinence occurring in younger children. There are many factors that can contribute to this condition which can affect up to 20% of children over 5 years old. Complementary Alternative Medicine (CAM) treatments offer potential benefits but need to be tested under scientific conditions to determine if they work and are safe. It is well documented that children have improved self-esteem, self-concept and self-care if they are able to reduce or resolve bed wetting issues. This leads to improvements in social relationships with family and peers. The main aim of the study is determine how effective an herbal capsule (listed by the Therapeutic Goods Administration - TGA) is at reducing or stopping bed-wetting at night by children. The target population for this study will be children aged 6 to 14 years old both male and female.